Literature DB >> 31534205

Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms.

Samantha N Champion1, James R Stone2.   

Abstract

Immune checkpoint inhibitor therapy for malignancy has been associated with adverse events including myocarditis. It has been unclear if there are distinct pathologic grades of this myocarditis that are associated with distinct clinical outcomes. Cardiac tissue from ten patients with immune checkpoint inhibitor myocarditis (nine biopsies and one autopsy) were evaluated using immunohistochemistry for CD3, CD8, CD68, tryptase, PD-L1, and C4D. The immune checkpoint inhibitor myocarditis cases were classified as either high grade (>50 CD3+ cells/hpf) or low grade (≤50 CD3+ cells/hpf). The densities of macrophages, T cells, eosinophils, necrotic myocytes, and PD-L1+ macrophages and myocytes were compared between the two groups and with 13 cases of grade 2R acute cellular allograft rejection. Three patients were classified as high-grade myocarditis and seven as low grade. There were higher densities of CD3+ cells and CD8+ cells in high-grade immune checkpoint inhibitor myocarditis and rejection compared with low-grade myocarditis. The number of CD68+ macrophages was higher in high-grade myocarditis compared with low-grade myocarditis and rejection. For both grades of myocarditis, there was a higher CD68/CD3 ratio and a higher density of PD-L1+ macrophages and myocytes compared with rejection. Clinically, there were trends toward higher serum troponin levels and shorter interval from first immune checkpoint inhibitor treatment in the high-grade myocarditis group compared with the low-grade group. All the patients with high-grade myocarditis died, while all the patients with low-grade myocarditis were still living. These data suggest that immune checkpoint inhibitor myocarditis occurs in two forms, a high-grade form with increased inflammatory cell infiltration and a more fulminant clinical course, and a low-grade form with a lower degree of inflammatory cell infiltration and a more indolent clinical course. Compared with acute cellular rejection, immune checkpoint inhibitor myocarditis is characterized by a more lymphohistiocytic inflammatory infiltrate with an increased CD68/CD3 ratio and increased PD-L1+ macrophages and myocytes.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31534205     DOI: 10.1038/s41379-019-0363-0

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  18 in total

Review 1.  PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.

Authors:  Hao Dong; Yihang Qi; Xiangyi Kong; Zhongzhao Wang; Yi Fang; Jing Wang
Journal:  Front Pharmacol       Date:  2022-04-19       Impact factor: 5.988

Review 2.  What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.

Authors:  Marina Frayberg; Anthony Yung; Leyre Zubiri; Daniel A Zlotoff; Kerry L Reynolds
Journal:  Curr Treat Options Oncol       Date:  2021-05-26

3.  Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis.

Authors:  Javid Moslehi; Joe-Elie Salem; John R Power; Joachim Alexandre; Arrush Choudhary; Benay Ozbay; Salim Hayek; Aarti Asnani; Yuichi Tamura; Mandar Aras; Jennifer Cautela; Franck Thuny; Lauren Gilstrap; Dimitri Arangalage; Steven Ewer; Shi Huang; Anita Deswal; Nicolas L Palaskas; Daniel Finke; Lorenz Lehman; Stephane Ederhy
Journal:  Circulation       Date:  2021-11-01       Impact factor: 29.690

4.  The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer.

Authors:  Lili Zhang; Kerry L Reynolds; Alexander R Lyon; Nicolas Palaskas; Tomas G Neilan
Journal:  JACC CardioOncol       Date:  2021-01-12

Review 5.  Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.

Authors:  Flora Pirozzi; Remo Poto; Luisa Aran; Alessandra Cuomo; Maria Rosaria Galdiero; Giuseppe Spadaro; Pasquale Abete; Domenico Bonaduce; Gianni Marone; Carlo Gabriele Tocchetti; Gilda Varricchi; Valentina Mercurio
Journal:  Curr Oncol Rep       Date:  2021-01-07       Impact factor: 5.075

Review 6.  Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes.

Authors:  Weijian Hang; Chen Chen; John M Seubert; Dao Wen Wang
Journal:  Signal Transduct Target Ther       Date:  2020-12-11

7.  Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation.

Authors:  Daniel Finke; Markus B Heckmann; Janek Salatzki; Johannes Riffel; Esther Herpel; Lucie M Heinzerling; Benjamin Meder; Mirko Völkers; Oliver J Müller; Norbert Frey; Hugo A Katus; Florian Leuschner; Ziya Kaya; Lorenz H Lehmann
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 8.  Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects.

Authors:  Wenlu Zou; Jie Lu; Yan Hao
Journal:  J Inflamm Res       Date:  2021-07-08

Review 9.  Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer.

Authors:  Katsiaryna Marhelava; Zofia Pilch; Malgorzata Bajor; Agnieszka Graczyk-Jarzynka; Radoslaw Zagozdzon
Journal:  Cancers (Basel)       Date:  2019-11-08       Impact factor: 6.639

10.  Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study.

Authors:  Cristina Basso; Ornella Leone; Stefania Rizzo; Monica De Gaspari; Allard C van der Wal; Marie-Christine Aubry; Melanie C Bois; Peter T Lin; Joseph J Maleszewski; James R Stone
Journal:  Eur Heart J       Date:  2020-10-14       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.